Tag Archives: Moderna

FDA and CDC advisors accuse Moderna of withholding trial data that suggested its Covid bivalent booster was LESS effective than older shot — to secure $5bn Government order, by Meike Leonard

Ethics apparently are out the window when $5 billion is on the line. From Meike Leonard at dailymail.co.uk:

  • Members of the Covid-19 advisory board claim crucial data was withheld
  • Omitted study showed that new booster was LESS effective than original jab 
  • Though data was limited, advisors say it should have been shown to them 
  • US taxpayers have forked out $5billion for new booster, with very low uptake
  • Vaccine advisory board say they’re ‘disappointed’ and ‘angry’ at omission 

Moderna and the Food and Drug Association (FDA) have been accused of concealing data during the approval process for the pharma giant’s bivalent Covid booster.

Vaccine advisors who signed off on the updated shot late last year claim they were not shown trial data that indicated the booster was actually less effective at preventing Covid than the older vaccine it was meant to replace.

While the early trial results had substantial limitations, ‘disappointed’ and ‘angry advisors say its omission from panel discussions shows a remarkable lack of transparency.

Continue reading→

Pfizer And Moderna To Investigate Their Own Vaccines For Myocarditis Risks, by Tyler Durden

Well this should clear up all the controversies. From Tyler Durden at zerohedge.com:

Why is Big Pharma investigating their own covid vaccines for myocarditis side effects if the vaccines were already supposedly tested and proven safe and effective?

Both Pfizer and Moderna have announced that they will be undertaking studies to determine the longer term risks of Myocarditis (an inflammatory condition of the heart which can lead to death) for people who have been injected with the mRNA based covid vaccines.  The decision comes after the release of multiple medical studies which show a correlation and causation between the vaccines and an exponential increase in heart problems, specifically among men 40 years old and younger.  Only a year ago the link between covid vaccinations and myocarditis was widely denied.

Studies also show that myocarditis risk increases with the number of boosters a person has taken.

Before the year 2020, the average vaccine was tested and re-tested by pharmaceutical companies and the FDA for 10 to 15 years before it could be released to the public.  This was done not only because testing is a complex process with a lot of red tape involved, but also because it is the only way to discover any long term side-effects that might be associated with a particular immunization product.  If you read any medical journal or scientific outline on vaccine development published before 2020, they all agree that long term testing is necessary for public safety.

Continue reading→

RNA for Moderna’s Omicron Booster Manufactured by CIA-Linked Company, by Whitney Webb

One of the best investigative journalists on the internet examines the ties between a new biotechnology firm and the CIA. From Whitney Webb at unlimitedhangout.com:

Since late last year, messenger RNA for Moderna’s COVID-19 vaccines, including its recently reformulated Omicron booster, has been exclusively manufactured by a little known company with significant ties to US intelligence.

Earlier this week, the United Kingdom became the first country to approve Moderna’s reformulated version of its COVID-19 vaccine, which claims to provide protection against both the original form of the virus and the significantly less lethal but more transmissible Omicron variant. The product was approved by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) with the support of the UK government’s Commission on Human Medicines.

Described by UK officials as a “sharpened tool” in the nation’s continued vaccination campaign, the reformulated vaccine combines the previously approved COVID-19 vaccine with a “vaccine candidate” targeting the Omicron variant BA.1. That vaccine candidate has never been previously approved and has not been the subject of independent study. The MHRA approved the vaccine based on a single, incomplete human trial currently being conducted by Moderna. The company promoted incomplete data from that trial in company press releases in June and July. The study has yet to be published in a medical journal or peer reviewed. No concerns have been raised by any regulatory agency, including the MHRA, regarding Moderna’s past history of engaging in suspect and likely illegal activity in past product trials, including for its original COVID-19 vaccine.

The approval comes shortly before several Western countries, including the UK, plan to conduct a massive COVID-19 booster vaccination campaign this fall. Moderna has also noted that approval for its Omicron booster vaccine are pending in the US, EU, Australia and Canada – all of which are also planning fall vaccination campaigns focused on COVID-19. The company’s CEO, Stéphane Bancel, has called the reformulated vaccine “our lead candidate for a Fall 2022 booster.”

Continue reading→

FDA Colluded With Moderna to Bypass COVID Vaccine Safety Standards, Documents Reveal, by Megan Redshaw

Ostensibly a regulatory agency, the FDA has become a subsidiary of the big drug companies. From Megan Redshaw at childrenshealthdefense.org:

According to Alexandra Latypova, an ex-pharmaceutical industry executive, documents obtained from the U.S. Department of Health and Human Services on Moderna’s COVID-19 vaccine suggest the U.S. Food and Drug Administration and Moderna colluded to bypass regulatory and scientific standards used to ensure products are safe.

According to an ex-pharmaceutical industry and biotech executive, documents obtained from the U.S. Department of Health and Human Services (HHS) on Moderna’s COVID-19 vaccine suggest the U.S. Food and Drug Administration (FDA) and Moderna colluded to bypass regulatory and scientific standards used to ensure products are safe.

Alexandra Latypova has spent 25 years in pharmaceutical research and development working with more than 60 companies worldwide to submit data to the FDA on hundreds of clinical trials.

After analyzing 699 pages of studies and test results “supposedly used by the FDA to clear Moderna’s mRNA platform-based mRNA-1273, or Spikevax,” Latypova told The Defender she believes U.S. health agencies are lying to the public on behalf of vaccine manufacturers.

“It is evident that the FDA and NIH [National Institutes of Health] colluded with Moderna to subvert the regulatory and scientific standards of drug safety testing,” Latypova said.

Continue reading→

Pfizer & Moderna Investors Run for the Exits, by Justus R. Hope

Is Wall Street beginning to smell a rat? Like, perhaps, that Covid vaccines are responsible for far more deaths and debilitating illnesses than anyone wants to admit, and that perhaps the manufacturers concealed data that would have raised red flags? From Justus R. Hope at thedesertreview.com:

Wall Street investors are dumping their Moderna and Pfizer stock faster than the world can drop the mandates. Moderna is down 70 percent from its high, while Pfizer is off 19 percent. Former Blackrock Executive and investment adviser Edward Dowd calls for Moderna to go to zero and Pfizer to end under ten dollars per share.

How is this possible given that Pfizer now enjoys record earnings per share and a market capitalization of some $270 billion, making it the 29th largest corporation globally? With nothing but profits in sight for the Pharmaceutical giant, what could be the problem?

After all, in December, a Forbes’ headline read, “The Vaccine Maker Can Dominate The Covid Market For Years to Come, Wells Fargo Predicts.” In addition to the enormously profitable mRNA vaccines, Pfizer is rolling out potent antivirals like Paxlovid, which could earn $22 billion in 2022.

https://www.forbes.com/sites/sergeiklebnikov/2021/12/09/this-vaccine-maker-can-dominate-the-covid-market-for-years-to-come-wells-fargo-predicts/

Compared to the $81 billion in 2021 revenue, the earnings from the vaccines and the antivirals could top $102 billion for 2022, which is music to shareholders’ ears. However some are hearing shrieks, and these happen to be Wall Street’s finest, the smart money that beats the rest of the herd to the exits like clockwork.

These sophisticated investors make it their business to not go with the conventional wisdom but to do their own research, which often pays spectacular dividends.

Edward Dowd is one such investor. He saw the dot com bubble ready to burst and acted accordingly. But, unfortunately, other not-so-savvy investors later saw their dot com heavy portfolios collapse as the NASDAQ Composite Index lost 40% of its value in 2000.

Dowd, a graduate of Notre Dame University and former Portfolio Manager at Blackrock, grew his fund from $2 billion to $14 billion and commanded the respect of his investment community peers.

Today, after semi-retiring to the shores of South Maui, he remains a voice of stock market wisdom that many hedge funds continue to rely upon. LinkedIn lists him as a Consultant to Founder & Partner of Symphonic Capital, LLC.

Continue reading→

FDA Duplicity on Covid-19 Vaccines, by Steve McCann

Nothing is more corrupt than a completely captured government agency. From Steve McCann at americanthinker.com:

Perhaps the most important long-term fallout of the Chinese Coronavirus pandemic has been the exposure of the venality and politicization within the Food and Drug Administration (FDA) as well as other federal health agencies such as the Centers for Disease Control (CDC).

Nothing personifies this corruption more than the FDA’s absurdly close ties to the pharmaceutical companies.  Thus, their refusal to recognize proven inexpensive therapeutics and their unorthodox approach in licensing certain Pfizer and Moderna mRNA Covid-19 — vaccines that are not offered for sale in the United States.

What was the FDA’s and the pharmaceutical companies’ endgame in this process?  Was it to gaslight the American people in order to sell vaccines and achieve mass vaccinations?   Was their motive to protect the pharmaceutical companies from exposure to liability and a tsunami of litigation?  Was it so the FDA could more easily approve these vaccines for children who are not at risk of Covid-19?  Or all the above?

In August of 2021, the FDA, to great media fanfare, granted permanent approval for a Pfizer Covid-19 vaccine.  The catch: it was for a vaccine that was not available to Americans.  What the FDA approved and licensed is Pfizer’s Comirnaty vaccine, not the Pfizer-BioNTech vaccine that has been continuously in use under Emergency Use Authorization (EUA) since December of 2020.  Manufacturers of medicines sold under an EUA are immunized from legal liability.

Continue reading→

‘Unconscionable’: Pfizer, Moderna to Rake in Combined $93 Billion in 2022 COVID Vaccine Sales, by Megan Redshaw

Do you wonder why the powers that be frantically stifle the advocacy and use of drugs like Ivermectin and Hydroxychloroquine. $93 billion gives the drug companies a lot of lucre to spread among the media companies (advertising) and politicians (bribes campaign contributions). From Megan Redshaw at childrenshealthdefense.org:

A report by health data analytics group, Airfinity, projects “unprecedented” sales and profits for Pfizer and Moderna in 2022. According to the People’s Vaccine Alliance, the companies are pricing their vaccines by as much as $41 billion above the estimated cost of production.

Vaccine makers Pfizer and Moderna are projected to generate combined sales of $93.2 billion in 2022 nearly twice the amount they’re expected to rake in this year, said Airfinity, a health data analytics group.

Airfinity put total market sales for COVID vaccines in 2022 at $124 billion, according to the Financial Times.

Pfizer vaccine sales are predicted to reach $54.5 billion in 2022, and Moderna’s will hit $38.7 billion. The estimates blow the earlier figures — $23.6 billion for Pfizer and $20 billion for Moderna — out of the water.

“The numbers are unprecedented,” Rasmus Beck Hansen, CEO of Airfinity, told the Financial Times.

Sales of the mRNA shots will continue to rise in 2022 due to boosters and countries stockpiling to ward off variants, Airfinity said.

Pfizer will generate 64% of its sales, and Moderna 75% of its sales, from high-income countries in 2022, the analysts predicted.

In April, Pfizer predicted 2021 COVID vaccine sales of $26 billion. After second-quarter results were reported, Pfizer upped the figure to $33.5 billion. Bernstein analyst Ronny Gal said the company could ring up an additional $10 billion in vaccine sales in 2021.

Continue reading→

Moderna: A Company “In Need Of A Hail Mary”, by Whitney Webb

Moderna had one foot in the financial grave before Covid-19 came along. From Whitney Webb at unlimitedhangout.com:

Before COVID-19, Moderna was in danger of hemorrhaging investors, as persistent safety concerns and other doubts about its mRNA delivery system threatened its entire product pipeline. Fear caused by the pandemic crisis made those concerns largely evaporate, even though there is no proof that they were ever resolved

Those analyzing the COVID-19 crisis and its effects have mostly focused on how its disruptive nature has led to major shifts and recalibrations throughout society and the economy. Such disruption has also lent itself to a variety of agendas that had required an event of “reset” potential in order to be realized. In the case of the vaccine industry, COVID-19 has led to dramatic changes in how federal agencies manage the approval of medical countermeasures during a declared crisis, how trials for vaccine candidates are conducted, how the public perceives vaccination, and even how the term “vaccine” is defined.

Such shifts, though obvious, have provoked praise from some and sharp criticism from others, with the latter category being largely censored from public discourse on television, in print, and online. However, in objectively analyzing such seismic changes, it’s clear that most of these shifts in vaccine development and vaccine policy dramatically favor speed and the implementation of new and experimental technology at the expense of safety and thorough study. In the case of vaccines, it can be argued that no one benefitted more from these changes than the developers of the COVID-19 vaccines themselves, particularly the pharmaceutical and biotechnology company Moderna.

Not only did the COVID-19 crisis obliterate hurdles that had previously prevented Moderna from taking a single product to market, it also dramatically reversed the company’s fortunes. Indeed, from 2016 right up until the emergence of COVID-19, Moderna could barely hold it together, as it was shedding key executives, top talent, and major investors at an alarming rate. Essentially, Moderna’s promise of “revolutionizing” medicine and the remarkable salesmanship and fund-raising capabilities of the company’s top executive, Stéphane Bancel, were the main forces keeping it afloat. In the years leading up to the COVID-19 crisis, Moderna’s promises—despite Bancel’s efforts—rang increasingly hollow, as the company’s long-standing penchant for extreme secrecy meant that—despite nearly a decade in business—it had never been able to definitively prove that it could deliver the “revolution” it had continually assured investors was right around the corner.

Continue reading→

Is Covid-19 a Bioweapon? by Joseph Mercola

Medical professionals should ponder the ethical and legal implications of prescribing an Emergency Use Authorization for which their patients’ consent can in no way be considered informed. From Joseph Mercola at lewrockwell.com:

Helping you take control of your health in these crazy times is Dr. Richard Fleming, a prolific author in addition to being a physicist, a nuclear cardiologist, researcher and attorney.

Here, we discuss his latest book “Is COVID-19 a Bioweapon? A Scientific and Forensic Investigation,” slated for release September 7, 2021. It’s currently available for preorder on Amazon. It’s an incredibly well-documented book and contains history that many of us aren’t aware of. As it turns out, the creation of this virus goes back not a year or two but two decades.

“My area of aptitude [is] physics and calculus, the mathematic language for that. Physics, and particularly high energy particle physics, is something that I find very fascinating.

I eventually wound up doing some of that later on in life as a nuclear cardiologist. So, [I’ve done] 53 years of research in physics, and in medicine, I actually developed the inflammation in heart disease theory and presented it to American Heart in 1994.

I joined American Heart in 1976 as the youngest faculty member at that time, and I got put in several standing committees as a result — basic and advanced cardiac life support as well as the physician cholesterol education faculty.

I did a lot of research on dietary influences and factors that are critical, not only for in the end — heart disease — but other chronic inflammatory diseases, be that cerebrovascular diseases, strokes, diabetes or cancer,” Fleming explains.

Continue reading→

At FDA Urging, Pfizer and Moderna to Include Thousands More Children in Clinical Trials, by Children’s Health Defense Team

There is no low to which they won’t sink. Now they’re using kids as guinea pigs. From the Children’s Health Defense Team at childrenshealthdefense.org:

Pfizer and Moderna will increase the number of children in their COVID vaccine clinical trials prior to seeking Emergency Use Authorization (EUA), after the U.S. Food and Drug Administration (FDA) told the vaccine makers the size and scope of their pediatric studies, as initially envisioned, were inadequate to detect rare side effects.

The rare side effects cited by the FDA include myocarditis, an inflammation of the heart muscle, and pericarditis, inflammation of the lining around the heart, multiple people familiar with the trials told The New York Times.

Moderna’s shot is authorized for emergency use in people 18 and up, and Pfizer’s vaccine is authorized for children as young as 12. No COVID vaccines have yet received EUA approval for children younger than 12.

Expanding the pediatric trials means thousands more children as young as 6 months old may soon be recruited and enrolled in COVID vaccine trials.

According to the Times, the FDA asked the companies to include 3,000 children in the 5- to 11-year-old group, the group for whom results were expected first.

One person, granted anonymity by the Times to speak freely, described that figure as double the original number of study participants.

Continue reading→